aluxum JPMorgan has added Revolution Medicines ( NASDAQ: RVMD ) to its Analyst Focus List in anticipation of several data releases in Q4 on non-small cell lung cancer candidate RMC-6236. The firm has an outperform rating on the stock and a $54 price target (~27% upside based on.
Back to Health Page
